Evidence map›Paper›PMID 34206803›Full record

ArticleLife (Basel, Switzerland)2021

Expression Status and Prognostic Value of m

Xiuhong Li, Zian Feng, Rui Wang, Jie Hu, Xiaodong He, Zuojun Shen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. The therapeutic potential of RNA m(6)A in lung cancer.Cell communication and signaling : CCS · 2024
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xiuhong LiDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Zian FengDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.ORCID 0000-0001-7780-2229
Rui WangDeparment of Clinical Laboratory, Anhui Provincial Hospital, Anhui Medical University, Hefei 230001, China.
Jie HuDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Xiaodong HeAnhui Provincial Center for Clinical Laboratories, Hefei 230001, China.
Zuojun ShenDepartment of Clinical Laboratory, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.ORCID 0000-0001-7052-5652
University of Science and Technology of China · CNAnhui Medical University · CN

Funding

Fundamental Research Funds for the Central Universities WK911000057Key Programs for Research and Development of Anhui Province No.1704a0802153Project of the Science and Technology Innovation of Anhui province 2017070802D146, 2018080402A009
6 · The paper itself

Abstract

N

Indexed as

lung adenocarcinomam6A methylationprognostic signaturesurvival analysis

Identifiers

PMID34206803
PMCPMC8306618
OpenAlexW3175327672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.